CN113908176A - Composition for preventing and treating food allergy - Google Patents
Composition for preventing and treating food allergy Download PDFInfo
- Publication number
- CN113908176A CN113908176A CN202111447581.XA CN202111447581A CN113908176A CN 113908176 A CN113908176 A CN 113908176A CN 202111447581 A CN202111447581 A CN 202111447581A CN 113908176 A CN113908176 A CN 113908176A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- bifidobacterium longum
- group
- animalis
- bifidobacterium animalis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000004262 Food Hypersensitivity Diseases 0.000 title claims abstract description 21
- 206010016946 Food allergy Diseases 0.000 title claims abstract description 21
- 235000020932 food allergy Nutrition 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 63
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 63
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 46
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 40
- 235000013305 food Nutrition 0.000 abstract description 25
- 229960001340 histamine Drugs 0.000 abstract description 20
- 230000028327 secretion Effects 0.000 abstract description 6
- 230000004069 differentiation Effects 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 3
- 241000186000 Bifidobacterium Species 0.000 abstract description 3
- 108090000978 Interleukin-4 Proteins 0.000 abstract description 3
- 230000036783 anaphylactic response Effects 0.000 abstract description 3
- 208000003455 anaphylaxis Diseases 0.000 abstract description 3
- 210000001165 lymph node Anatomy 0.000 abstract description 3
- 210000003714 granulocyte Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 29
- 239000000902 placebo Substances 0.000 description 26
- 229940068196 placebo Drugs 0.000 description 26
- 239000006041 probiotic Substances 0.000 description 26
- 235000018291 probiotics Nutrition 0.000 description 26
- 230000000529 probiotic effect Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 16
- 230000000172 allergic effect Effects 0.000 description 15
- 208000010668 atopic eczema Diseases 0.000 description 15
- 238000000034 method Methods 0.000 description 11
- 206010020751 Hypersensitivity Diseases 0.000 description 10
- 239000013566 allergen Substances 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000003266 anti-allergic effect Effects 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 238000000703 high-speed centrifugation Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- 241001156739 Actinobacteria <phylum> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010061711 Gliadin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229910052564 epsomite Inorganic materials 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a composition for preventing and treating food allergy, which comprises bifidobacterium longum and bifidobacterium animalis; the latin name of bifidobacterium longum: bifidobacterium longum, deposit number: CICC 6188; the latin name of bifidobacterium animalis: bifidobacterium animalis, deposit No.: CICC 6165. The composition can effectively inhibit Th0 from differentiating to Th2, remarkably regulate and increase IgE and IL-4, enhance Treg differentiation and IL-10 secretion in mesenteric lymph node, and reduce basophilic granulocyte histamine secretion to reduce food anaphylaxis by synergistic effect of Bifidobacterium longum and animal Bifidobacterium.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a composition for preventing and treating food allergy.
Background
Food allergy is a common immunological disease worldwide with pathological, potentially fatal allergic reactions caused by normal food. Most food allergens have high heat and pH stability, high sequence conservation, and varying degrees of cross-reactivity between species.
Currently, the methods for alleviating and controlling the allergy caused by various allergens in food are generally adopted to avoid the consumption of corresponding allergens and products thereof, to remove the corresponding allergens from food and to clinically use antiallergic drugs for treatment. Avoiding the consumption of food and products containing allergen can effectively reduce the probability of allergy occurrence, but cannot fundamentally avoid the consumption of one food. The method for removing the allergen from the food can obviously reduce the immunological activity of the allergen, but cannot fundamentally relieve or control the food allergy, and easily leads the food to lose the structure, sensory properties and nutritional value of the food. Clinical therapeutic administration is mainly specific immunotherapy to induce the body to tolerate allergens, which can cause allergic reactions of different degrees when the host is contacted with the allergens again.
Disclosure of Invention
The present invention is directed to solving, at least to some extent, one of the technical problems in the related art. To this end, it is an object of the present invention to provide a composition for the prevention and treatment of food allergy.
In a first aspect of the invention, a composition for the prevention and treatment of food allergy is presented, comprising bifidobacterium longum and bifidobacterium animalis; the latin name of bifidobacterium longum: bifidobacterium longum, deposit number: CICC 6188; the latin name of bifidobacterium animalis: bifidobacterium animalis, deposit No.: CICC 6165.
According to the composition for preventing and treating allergy, through the synergistic effect of bifidobacterium longum and bifidobacterium animalis, the differentiation from Th0 to Th2 can be effectively inhibited, IgE and IL-4 are obviously regulated and increased, Treg differentiation and IL-10 secretion in mesenteric lymph nodes are enhanced, and basophilic histamine secretion is reduced, so that food anaphylaxis is reduced, and the intestinal environment of a human body is regulated or improved to achieve the effect of resisting allergy.
Optionally, the bifidobacterium longum and the bifidobacterium animalis are present in a ratio of 1: 1 proportion of 1, the intake is 1 × 10 per day10～1×1013cfu。
In a second aspect of the invention, a medicament for the prevention and treatment of food allergy is provided, comprising bifidobacterium longum and bifidobacterium animalis; the latin name of bifidobacterium longum: bifidobacterium longum, deposit number: CICC 6188; the latin name of bifidobacterium animalis: bifidobacterium animalis, deposit No.: CICC 6165.
According to the medicament for preventing and treating allergy, by the synergistic effect of bifidobacterium longum and bifidobacterium animalis, the differentiation from Th0 to Th2 can be effectively inhibited, IgE and IL-4 are obviously regulated and increased, Treg differentiation and IL-10 secretion in mesenteric lymph nodes are enhanced, and basophilic histamine secretion is reduced, so that food anaphylaxis is reduced, and the intestinal environment of a human body is regulated or improved to achieve the anti-allergy effect.
Optionally, the medicament is in one of a tablet, a granule, a powder, a capsule, a solution, a suspension, and a lyophilized preparation.
Optionally, the composition further comprises pharmaceutically acceptable auxiliary agents, wherein the auxiliary agents comprise at least one of stabilizing agents, wetting agents, emulsifying agents and binding agents.
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Drawings
FIG. 1 is a graph showing the effect of Bifidobacterium longum and Bifidobacterium animalis on specific IgE in the serum of allergic patients according to example 2 of the present invention;
FIG. 2 is a graph showing the effect of histamine content in the serum of Bifidobacterium longum and Bifidobacterium animalis allergic patients in example 3 according to the invention;
FIG. 3 is a graph showing the effect of specific IgE in the serum of Bifidobacterium longum allergy patients in accordance with example 4 of the present invention;
FIG. 4 is a graph showing the effect of histamine content in serum of Bifidobacterium longum allergic patients in example 5 according to the present invention.
Detailed Description
The technical solution of the present invention is illustrated by specific examples below. It is to be understood that one or more method steps mentioned in the present invention do not exclude the presence of other method steps before or after the combination step or that other method steps may be inserted between the explicitly mentioned steps; it should also be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Moreover, unless otherwise indicated, the numbering of the various method steps is merely a convenient tool for identifying the various method steps, and is not intended to limit the order in which the method steps are arranged or the scope of the invention in which the invention may be practiced, and changes or modifications in the relative relationship may be made without substantially changing the technical content.
In order to better understand the above technical solutions, exemplary embodiments of the present invention are described in more detail below. While exemplary embodiments of the invention have been shown, it should be understood that the invention may be embodied in various forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
The test materials adopted by the invention are all common commercial products and can be purchased in the market.
The invention will now be described with reference to specific examples, which are intended to be illustrative only and not to be limiting in any way.
Example 1
First, isolation of the Strain
(1) Sampling the naturally fermented yoghourt by using a sterilized sampling spoon, avoiding other parts from contacting with a sample in the sampling process so as to prevent pollution, placing 1mL of the naturally fermented yoghourt in a triangular flask with 99mL of sterile physiological saline with the concentration of 0.85% under an aseptic condition, and oscillating for 15min to fully and uniformly mix the sample to prepare a suspension; diluting the suspension by 10-fold serial gradient dilution method, uniformly coating 100 μ L of each gradient on MRS peptone 10g, beef powder 5g, and K2HPO4·7H2O2 g, triammonium citrate 2g, CH3COONa·3H2O5 g, glucose 20g, Tween 801 mL, MgSO4·7H2O 0.2g、MnSO4·4H20.05g of O and 1000mL of distilled water, then placing the plate culture medium in an anaerobic jar, carrying out anaerobic culture at 37 ℃ overnight, and observing that characteristic colonies (characterized by medium size, convex and slight white of the colonies,moistening, tidy edges, round bacterial colony with diameter of 1.5mm +/-1 mm); and (3) performing second-generation streak inoculation on the selected characteristic bacterial colony according to the inoculation amount of 1 percent, and inoculating the characteristic bacterial colony on an MRS plate culture medium for purification treatment, and performing anaerobic activation at 37 ℃ for 1 day to obtain a culture for later use.
(2) Primer: 27F: 5'AGAGTTTGATCMTGGCTCAG 3'; 1492R: 5'GGTTACCTTGTTACGACTT 3'. Extracting DNA of the culture by using a bacterial DNA kit, carrying out PCR amplification on the 16SrDNA fragment to obtain an amplification product, and then sending the amplification product to a biological engineering corporation of Ltd for sequencing to obtain the full length of the 16 SrDNA. 16SrDNA is subjected to Blast comparison in an Eztaxon database, and homology comparison is carried out, wherein the strains belong to Bifidobacterium longum (Bifidobacterium longum) and Bifidobacterium animalis (Bifidobacterium animalis) respectively, and the classification units of the strains are respectively as follows: (ii) Bacteria; actinomycetes; actinobacteria; bifidobacteria; a bidobacteraceae; bifidobacterium longum and Bacteria; actinomycetes; actinobacteria; bifidobacteria; a bidobacteraceae; bifidobacterium animalis.
Example 2
(1) 10 food allergy patients were taken as subjects, and 10 patients were randomly divided into a control group (3 persons), a placebo group (3 persons), and a probiotic group (4 persons). During the test period, the probiotic group subjects took an individually packaged 1: 1 Bifidobacterium longum and Bifidobacterium animalis (2g, viable count of 0.5X 10)13CFU/g), placebo subjects took placebo powder (dried porous dextrin 2g) daily for 28 consecutive days within 1 hour of a lunch meal. The food consumed by all groups remained consistent before and during the test. Blood samples of the subjects were collected on day 28 after taking probiotics or placebo and subjected to high speed centrifugation to obtain serum for immunoassay.
(2) Specific IgE assay in serum: the measurement was carried out by enzyme-linked immunosorbent assay (ELISA method). Wheat gliadin was diluted to 15 μ g/mL with PBS, then fixed in 96-well plates overnight at 4 ℃, washed 3 times with 200 μ L PBS, and blocked with 200 μ L5% BSA for 2h at 25 ℃. Thereafter, the plates were washed 3 times and incubated with 100 μ L of serum from 10 subjects (1:30 dilution) at 37 ℃ for 1.5 hours, and non-allergic serum was used as a negative control. After 3 washes, 100. mu.L of HRP-conjugated goat anti-human IgE (1:5000) was added to each well and incubated at 37 ℃ for 1.5 hours. Then 100. mu.L of tetramethylbenzidine solution was added to each well and incubated at 37 ℃ for 15 minutes. The color reaction was stopped by 50. mu.L of 2M H2SO4 solution. The optical density of each well was measured at 450nm using a microplate reader (Molecular Devices, USA).
The results are shown in fig. 1, compared with the control group, the serum IgE level of the food allergic population of the placebo group has no significant change, and the serum IgE level of the food allergic population of the probiotic group after the intervention of the bifidobacterium longum and the bifidobacterium animalis for 28 days is significantly lower than that of the control group and the placebo group. The intervention of the bifidobacterium longum and the bifidobacterium animalis has the regulation effect on food allergy patients and can regulate or improve the intestinal environment of human bodies to achieve the anti-allergic effect.
Example 3
(1) 10 food allergy patients were taken as subjects, and 10 patients were randomly divided into a control group (3 persons), a placebo group (3 persons), and a probiotic group (4 persons). During the test period, the probiotic group subjects took an individually packaged 1: 1 Bifidobacterium longum and Bifidobacterium animalis (4g, viable count of 1X 10)13CFU/g), placebo subjects took placebo powder (4g of oven-dried porous dextrin) daily for 28 consecutive days within 1 hour of a lunch meal. The food consumed by all groups remained consistent before and during the test. Blood samples of the subjects were collected on day 28 after taking probiotics or placebo and subjected to high speed centrifugation to obtain serum for immunoassay.
(2) Determination of histamine in serum: determination of histamine in serum human histamine ELISA kit (purchased from Thermo Fisher Scientific) was used, according to the instructions, and the absorbance OD at 450nm was determined for each well.
The results are shown in fig. 2, compared with the control group, the histamine level in the serum of the food allergic population of the placebo group has no significant change, and the histamine level in the serum of the food allergic population of the probiotic group after the intervention of bifidobacterium longum and bifidobacterium animalis for 28 days is significantly lower than that of the control group and the placebo group. The intervention of the bifidobacterium longum and the bifidobacterium animalis has the regulation effect on food allergy patients and can regulate or improve the intestinal environment of human bodies to achieve the anti-allergic effect.
Example 4
(1) 10 food allergy patients were taken as study subjects, and 10 patients were randomly divided into a control group (3 people), a placebo group (3 people), a probiotic group (4 people), a bifidobacterium longum group (4 people), and a bifidobacterium animalis group (4 people). During the test period, the probiotic group subjects took an individually packaged 1: 1 Bifidobacterium longum and Bifidobacterium animalis (2g, viable count of 0.5X 10)13CFU/g), administering separately packaged Bifidobacterium longum (2g, viable count of 0.5 × 10) to subject of Bifidobacterium longum group within 1 hr of each day after lunch13CFU/g), administering separately packaged Bifidobacterium longum (2g, viable count of 0.5 × 10) to the subject in Bifidobacterium animalis group within 1 hr after lunch13CFU/g), placebo subjects took placebo powder (dried porous dextrin 2g) daily for 28 consecutive days within 1 hour of a lunch meal. The food consumed by all groups remained consistent before and during the test. Blood samples of the subjects were collected on day 28 after taking probiotics or placebo and subjected to high speed centrifugation to obtain serum for immunoassay.
(2) Specific IgE assay in serum: the measurement was carried out by enzyme-linked immunosorbent assay (ELISA method). Wheat gliadin was diluted to 15 μ g/mL with PBS, then fixed in 96-well plates overnight at 4 ℃, washed 3 times with 200 μ L PBS, and blocked with 200 μ L5% BSA for 2h at 25 ℃. Thereafter, the plates were washed 3 times and incubated with 100 μ L of serum from 10 subjects (1:30 dilution) at 37 ℃ for 1.5 hours, and non-allergic serum was used as a negative control. After 3 washes, 100. mu.L of HRP-conjugated goat anti-human IgE (1:5000) was added to each well and incubated at 37 ℃ for 1.5 hours. Then 100. mu.L of tetramethylbenzidine solution was added to each well and incubated at 37 ℃ for 15 minutes. The color reaction was stopped by 50. mu.L of 2M H2SO4 solution. The optical density of each well was measured at 450nm using a microplate reader (Molecular Devices, USA).
The results are shown in fig. 3, compared with the control group, the histamine level in the serum of the food allergic population of the placebo group has no significant change, the histamine level in the serum of the food allergic population of the probiotic group after the intervention of the probiotic group of bifidobacterium longum and bifidobacterium animalis is significantly lower than that of the control group and the placebo group after 28 days, and the histamine level in the serum of the food allergic population of the probiotic group after the intervention of the bifidobacterium longum is lower than that of the control group and the placebo group, but the overall level is not high. The bifidobacterium longum, the bifidobacterium longum group and the probiotic group can intervene to regulate food allergy, regulate or improve the intestinal environment of a human body to achieve the antiallergic effect, but the effects of the bifidobacterium longum, the bifidobacterium longum group and the probiotic group are different, and the probiotic group has significant difference with the bifidobacterium longum group and the bifidobacterium animalis, so that the bifidobacterium longum and the bifidobacterium animalis have synergistic effect and better effect than the effect of a single bifidobacterium longum group and the effect of a single bifidobacterium animalis.
Example 5
(1) With 14 food allergy patients as study subjects, 10 patients were randomized into control group (3 people), placebo group (3 people), probiotic group (4 people), bifidobacterium longum group (4 people) and bifidobacterium animalis group (4 people). During the test period, the probiotic group subjects took an individually packaged 1: 1 Bifidobacterium longum and Bifidobacterium animalis (4g, viable count of 1X 10)13CFU/g), administering separately packaged Bifidobacterium longum (4g, viable count of 1 × 10) to subject of Bifidobacterium longum group within 1 hour of each day after lunch13CFU/g), administering separately packaged Bifidobacterium longum (4g, viable count of 1 × 10) to the subjects in Bifidobacterium animalis group within 1 hour of each day after lunch13CFU/g), placebo subjects took placebo powder (4g of oven-dried porous dextrin) daily for 28 consecutive days within 1 hour of a lunch meal. The food consumed by all groups remained consistent before and during the test. Blood samples of the subjects were collected on day 28 after taking probiotics or placebo and subjected to high speed centrifugation to obtain serum for immunoassay.
(2) Determination of histamine in serum: determination of histamine in serum human histamine ELISA kit (purchased from Thermo Fisher Scientific) was used, according to the instructions, and the absorbance OD at 450nm was determined for each well.
The results are shown in fig. 4, compared with the control group, the histamine level in the serum of the food allergic population of the placebo group has no significant change, the histamine level in the serum of the food allergic population of the probiotic group after the intervention of the probiotic group of bifidobacterium longum and bifidobacterium animalis for 28 days is significantly lower than that of the control group and the placebo group, and the histamine level in the serum of the food allergic population of the probiotic group after the intervention of the bifidobacterium longum for 28 days is lower than that of the control group and the placebo group, but the overall level is not high. The bifidobacterium longum, the bifidobacterium longum group and the probiotic group can intervene to regulate food allergy, regulate or improve the intestinal environment of a human body to achieve the antiallergic effect, but the effects of the bifidobacterium longum, the bifidobacterium longum group and the probiotic group are different, and the probiotic group has significant difference with the bifidobacterium longum group and the bifidobacterium animalis, so that the bifidobacterium longum and the bifidobacterium animalis have synergistic effect and better effect than the effect of a single bifidobacterium longum group and the effect of a single bifidobacterium animalis.
In conclusion, the bifidobacterium longum and the bifidobacterium animalis of the embodiment of the invention can obviously show the allergic reaction specific antibody IgE of the food allergy patient and the content of histamine in serum, thereby relieving the allergic reaction. Therefore, the Bifidobacterium longum and Bifidobacterium animalis can be used for relieving food allergy.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above should not be understood to necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples described in this specification can be combined and combined by those skilled in the art.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (5)
1. A composition for preventing and treating food allergy comprises Bifidobacterium longum and Bifidobacterium animalis; the latin name of bifidobacterium longum: bifidobacterium longum, deposit number: CICC 6188; the latin name of bifidobacterium animalis: bifidobacterium animalis, deposit No.: CICC 6165.
2. The composition of claim 1, wherein the bifidobacterium longum and the bifidobacterium animalis are present in a ratio of 1: 1 proportion of 1, the intake is 1 × 10 per day10～1×1013cfu。
3. A medicine for preventing and treating food allergy is characterized by comprising bifidobacterium longum and bifidobacterium animalis; the latin name of bifidobacterium longum: bifidobacterium longum, deposit number: CICC 6188; the latin name of bifidobacterium animalis: bifidobacterium animalis, deposit No.: CICC 6165.
4. The medicament of claim 3, wherein the medicament is in one of a tablet, granule, powder, capsule, solution, suspension, and lyophilized formulation.
5. The medicament of claim 3, further comprising pharmaceutically acceptable adjuvants including at least one of stabilizers, wetting agents, emulsifiers, binders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111447581.XA CN113908176B (en) | 2021-11-30 | 2021-11-30 | Composition for preventing and treating food allergy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111447581.XA CN113908176B (en) | 2021-11-30 | 2021-11-30 | Composition for preventing and treating food allergy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113908176A true CN113908176A (en) | 2022-01-11 |
| CN113908176B CN113908176B (en) | 2024-02-09 |
Family
ID=79248525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111447581.XA Active CN113908176B (en) | 2021-11-30 | 2021-11-30 | Composition for preventing and treating food allergy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113908176B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118240715A (en) * | 2024-05-29 | 2024-06-25 | 善恩康生物科技（苏州）有限公司 | Bifidobacterium longum and application thereof in relieving allergy |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120183506A1 (en) * | 2009-05-11 | 2012-07-19 | Nestec S.A. | Prevention and treatment of allergic diarrhoea |
| CN103275893A (en) * | 2013-05-06 | 2013-09-04 | 哈尔滨美华生物技术股份有限公司 | Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants |
| CN103820357A (en) * | 2013-12-30 | 2014-05-28 | 上海交大昂立股份有限公司 | Long bifidobacterium and function thereof for prevention and treatment of food allergy |
| US20160303226A1 (en) * | 2013-11-25 | 2016-10-20 | Nestec S.A. | Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations |
| CN107022501A (en) * | 2016-05-03 | 2017-08-08 | 深圳市儿童医院 | Application of the bifidobacterium infantis in food hypersenstivity food or medicine is prevented and treated |
| CN108770974A (en) * | 2018-06-15 | 2018-11-09 | 广东燕岭生命科技股份有限公司 | A kind of antianaphylactic probiotic gel candy and preparation method thereof |
| CN112273657A (en) * | 2019-07-22 | 2021-01-29 | 安琪酵母股份有限公司 | Probiotic composition for preventing or improving allergic diseases, preparation method and application |
| CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
-
2021
- 2021-11-30 CN CN202111447581.XA patent/CN113908176B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120183506A1 (en) * | 2009-05-11 | 2012-07-19 | Nestec S.A. | Prevention and treatment of allergic diarrhoea |
| CN103275893A (en) * | 2013-05-06 | 2013-09-04 | 哈尔滨美华生物技术股份有限公司 | Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants |
| US20160303226A1 (en) * | 2013-11-25 | 2016-10-20 | Nestec S.A. | Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations |
| CN103820357A (en) * | 2013-12-30 | 2014-05-28 | 上海交大昂立股份有限公司 | Long bifidobacterium and function thereof for prevention and treatment of food allergy |
| CN107022501A (en) * | 2016-05-03 | 2017-08-08 | 深圳市儿童医院 | Application of the bifidobacterium infantis in food hypersenstivity food or medicine is prevented and treated |
| CN108770974A (en) * | 2018-06-15 | 2018-11-09 | 广东燕岭生命科技股份有限公司 | A kind of antianaphylactic probiotic gel candy and preparation method thereof |
| CN112273657A (en) * | 2019-07-22 | 2021-01-29 | 安琪酵母股份有限公司 | Probiotic composition for preventing or improving allergic diseases, preparation method and application |
| CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118240715A (en) * | 2024-05-29 | 2024-06-25 | 善恩康生物科技（苏州）有限公司 | Bifidobacterium longum and application thereof in relieving allergy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113908176B (en) | 2024-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2539514C2 (en) | Nutritional composition containing strains bifidobacterium longum and relieving symptoms of food allergy, especially in infants and children | |
| JP5117171B2 (en) | Antiallergic lactic acid bacteria | |
| Reygagne et al. | The positive benefit of Lactobacillus paracasei NCC2461 ST11 in healthy volunteers with moderate to severe dandruff | |
| TWI542353B (en) | Anti-vaginitis food composition and pharmaceutical composition containing lactobacillus | |
| AU2006234793B2 (en) | Selection and use of lactic acid bacteria for reducing inflammation in mammals | |
| CN112375722B (en) | Lactobacillus casei LC-12 for improving allergy, and product and application thereof | |
| CN115029260B (en) | Lactobacillus gasseri with anti-inflammatory and antioxidant properties and application thereof | |
| CN101328468A (en) | Antiallergic lactic acid bacteria | |
| Rodríguez et al. | Infectious mastitis during lactation: a mammary dysbiosis model | |
| JP2008502606A (en) | Lactic acid bacteria and their use in the prevention of diarrhea | |
| Yoshida et al. | Clinical effects of probiotic Bifidobacterium breve supplementation in adult patients with atopic dermatitis | |
| CN113908176B (en) | Composition for preventing and treating food allergy | |
| Piano et al. | Comparison of the kinetics of intestinal colonization by associating 5 probiotic bacteria assumed either in a microencapsulated or in a traditional, uncoated form | |
| CN113337440B (en) | Lactobacillus salivarius MG-587 and application thereof | |
| JP2010518151A (en) | Use of Lactobacillus casei to increase the protection afforded by influenza vaccines | |
| CN110960561B (en) | Probiotic composition for regulating balance of gynecological flora | |
| TWI451871B (en) | Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing lactobacillus | |
| CN115786175B (en) | Lactobacillus mucosae and application thereof | |
| CN114806953B (en) | Lactobacillus gasseri with effect of improving type 1 diabetes | |
| TWI793595B (en) | Probiotic extracellular vesicles and the use thereof | |
| TWI815042B (en) | Use of leuconostoc mesenteroides tci007 metabolite for improving allergy | |
| CN115305211A (en) | Probiotics extracellular exosomes and uses thereof | |
| CN114317326B (en) | Lactobacillus sake for relieving anaphylactic reaction and preparation method thereof | |
| AU2019257482B2 (en) | Composition for promoting glucolipid metabolism, and preparation and application thereof | |
| CN113005066A (en) | Compound bifidobacterium preparation with antiallergic, immunity enhancing, blood sugar reducing, blood fat reducing and weight losing functions and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |